IP Library Granted Patent US 9,101,655
Granted Patent B2
US 9,101,655 · App. 13/912,499 · Granted Aug 11, 2015

Methods and compositions for treating mammalian nerve tissue injuries

Inventors: Riyi Shi (West Lafayette, IN); Richard B. Borgens (Delphi, IN)
Assignee: Purdue Research Foundation
A61K31/765A61K31/00A61K31/74A61K31/77
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,101,655
App. No.
13/912,499
Granted
Aug 11, 2015
Kind
B2
Abstract

To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.

Claims (14)

1. A method for treating an injury to nerve tissue of a mammalian patient, the method comprising administering an effective amount of a composition comprising polyethylene glycol to the patient so that the polyethylene glycol is delivered via the patient's vascular system to the site of the injured nerve tissue and wherein the polyethylene glycol is about 15% to about 50% by weight in the composition.

2. The method of claim 1 , wherein said polyethylene glycol is in a pharmaceutically acceptable carrier.

3. The method of claim 2 , wherein said carrier is water.

4. The method of claim 1 , wherein delivery by way of the patient's vascular system is effected by intravascular injection.

5. The method of claim 4 , wherein the intravascular injection comprises an intravenous injection.

6. The method of claim 1 , wherein delivery by way of the patient's vascular system is effected by intramuscular injection.

7. The method of claim 1 , wherein delivery by way of the patient's vascular system is effected by subcutaneous injection.

8. The method of claim 1 , wherein delivery by way of the patient's vascular system is effected by intraperitoneal injection.

9. The method of claim 1 , wherein the injured nerve tissue is spinal cord tissue.

10. The method of claim 1 , wherein the injured nerve tissue is peripheral nerve tissue.

11. The method of claim 1 , wherein the injury comprises a mechanical injury.

12. The method of claim 1 , wherein the injury comprises a biochemical injury.

13. The method of claim 1 , wherein the injury comprises an ischemic injury.

14. The method of claim 1 , wherein the wherein the polyethylene glycol is at least 30% by weight in the composition.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2014
From: SHI, RIYI; BORGENS, RICHARD B.
To: PURDUE RESEARCH FOUNDATION
Reel/Frame 032374/0959 →
CONFIRMATORY LICENSE Recorded Jun 19, 2013
From: PURDUE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030657/0546 →
Continuity (6)
Continuation 12508184 · Jul 23, 2009
Continuation In Part 09438206 · Nov 12, 1999
Continuation 10132542 · Apr 24, 2002
Provisional Application 60108145 · Nov 12, 1998
Provisional Application 60286200 · Apr 24, 2001
Related Publication 20140100289A1 · Apr 10, 2014